Katherine A. Kelly BSa, Leah Edenfield PharmDb, Mary Beth Seegars MDb, Rakhee Vaidya MBBSb, Steven R. Feldman MD, PhDa,c,d,e, Lindsay C. Strowd MDa
aCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC bDepartment of Internal Medicine, Section on Hematology/Oncology, Wake Forest School of Medicine, Winston-Salem, NC cDepartment of Pathology, Wake Forest School of Medicine, Winston-Salem, NC
dDepartment of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC
eDepartment of Dermatology, University of Southern Denmark, Odense, Denmark
Abstract
Background: Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody that appears to be more effective against CD30-expressing cutaneous T-cell lymphoma (CTCL) compared to current standard-of-care treatments.
Objective: To determine the real-world efficacy and adverse effects of BV use in patients with mycosis fungoides (MF) who were treated with BV at Atrium Health Wake Forest Baptist Medical Center.
Methods: Study staff performed a retrospective chart review of patients diagnosed with MF who were prescribed BV at Atrium Health Wake Forest Baptist Comprehensive Cancer Center.
Results: Regardless of their response to BV, all patients in our cohort had higher CD30 positivity on subsequent biopsies compared to their initial skin biopsy.
Conclusions: Improved understanding of appropriate CD30 testing and evaluation will allow for quicker invention of patients with BV responsive CTCL.
Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody conjugated with monomethyl auristatin E by a protease-cleavable linker.1 CD30 has a variable association with other cutaneous T-cell malignancies including mycosis fungoides (MF) and sezary syndrome (SS), making it a potential target for therapy.2 In this study we performed a retrospective chart review of patients with MF who were treated with BV at Atrium Health Wake Forest Baptist Medical Center to determine real-world efficacy and safety of BV use in this patient population.
